Literature DB >> 35183062

Librator: a platform for the optimized analysis, design, and expression of mutable influenza viral antigens.

Lei Li1,2, Siriruk Changrob1,2, Yanbin Fu1,2, Olivia Stovicek1, Jenna J Guthmiller1, Joshua J C McGrath2, Haley L Dugan3, Christopher T Stamper3, Nai-Ying Zheng1,2, Min Huang1, Patrick C Wilson1,3,2.   

Abstract

Artificial mutagenesis and protein engineering have laid the foundation for antigenic characterization and universal vaccine design for influenza viruses. However, many methods used in this process require manual sequence editing and protein expression, limiting their efficiency and utility in high-throughput applications. More streamlined in silico tools allowing researchers to properly analyze and visualize influenza viral protein sequences with accurate nomenclature are necessary to improve antigen design and productivity. To address this need, we developed Librator, a system for analyzing and designing custom protein sequences of influenza virus hemagglutinin (HA) and neuraminidase (NA) glycoproteins. Within Librator's graphical interface, users can easily interrogate viral sequences and phylogenies, visualize antigen structures and conservation, mutate target residues and design custom antigens. Librator also provides optimized fragment design for Gibson Assembly of HA and NA expression constructs based on peptide conservation of all historical HA and NA sequences, ensuring fragments are reusable and compatible across related subtypes, thereby promoting reagent savings. Finally, the program facilitates single-cell immune profiling, epitope mapping of monoclonal antibodies and mosaic protein design. Using Librator-based antigen construction, we demonstrate that antigenicity can be readily transferred between HA molecules of H3, but not H1, lineage viruses. Altogether, Librator is a valuable tool for analyzing influenza virus HA and NA proteins and provides an efficient resource for optimizing recombinant influenza antigen synthesis.
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Gibson Assembly; artificial mutagenesis; influenza; sequence design; protein engineering; system biology

Mesh:

Substances:

Year:  2022        PMID: 35183062      PMCID: PMC8921739          DOI: 10.1093/bib/bbac028

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   13.994


  48 in total

1.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

2.  Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.

Authors:  Yao-Qing Chen; Teddy John Wohlbold; Nai-Ying Zheng; Min Huang; Yunping Huang; Karlynn E Neu; Jiwon Lee; Hongquan Wan; Karla Thatcher Rojas; Ericka Kirkpatrick; Carole Henry; Anna-Karin E Palm; Christopher T Stamper; Linda Yu-Ling Lan; David J Topham; John Treanor; Jens Wrammert; Rafi Ahmed; Maryna C Eichelberger; George Georgiou; Florian Krammer; Patrick C Wilson
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

3.  Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Authors:  Rong Hai; Florian Krammer; Gene S Tan; Natalie Pica; Dirk Eggink; Jad Maamary; Irina Margine; Randy A Albrecht; Peter Palese
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

4.  Influenza virus vaccine based on the conserved hemagglutinin stalk domain.

Authors:  John Steel; Anice C Lowen; Taia T Wang; Mark Yondola; Qinshan Gao; Kester Haye; Adolfo García-Sastre; Peter Palese
Journal:  MBio       Date:  2010-05-18       Impact factor: 7.867

5.  Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans.

Authors:  Thomas Hagan; Mario Cortese; Nadine Rouphael; Carolyn Boudreau; Caitlin Linde; Mohan S Maddur; Jishnu Das; Hong Wang; Jenna Guthmiller; Nai-Ying Zheng; Min Huang; Amit A Uphadhyay; Luiz Gardinassi; Caroline Petitdemange; Michele Paine McCullough; Sara Jo Johnson; Kiran Gill; Barbara Cervasi; Jun Zou; Alexis Bretin; Megan Hahn; Andrew T Gewirtz; Steve E Bosinger; Patrick C Wilson; Shuzhao Li; Galit Alter; Surender Khurana; Hana Golding; Bali Pulendran
Journal:  Cell       Date:  2019-09-05       Impact factor: 41.582

6.  Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses.

Authors:  Rafael A Medina; Silke Stertz; Balaji Manicassamy; Petra Zimmermann; Xiangjie Sun; Randy A Albrecht; Hanni Uusi-Kerttula; Osvaldo Zagordi; Robert B Belshe; Sharon E Frey; Terrence M Tumpey; Adolfo García-Sastre
Journal:  Sci Transl Med       Date:  2013-05-29       Impact factor: 17.956

7.  MEGA11: Molecular Evolutionary Genetics Analysis Version 11.

Authors:  Koichiro Tamura; Glen Stecher; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2021-06-25       Impact factor: 16.240

8.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

Review 9.  B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat.

Authors:  Jenna J Guthmiller; Henry A Utset; Patrick C Wilson
Journal:  Viruses       Date:  2021-05-22       Impact factor: 5.048

10.  Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses.

Authors:  Lyubov Popova; Kenneth Smith; Ann H West; Patrick C Wilson; Judith A James; Linda F Thompson; Gillian M Air
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.